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Abstract Surfactant therapy has significantly changed
clinical practice in neonatology over the last 25 years.
Recent trials in infants with respiratory distress syndrome
(RDS) have not shown superiority of any natural surfactant
over another. Advancements in the development of syn-
thetic surfactants are promising, yet to date none has been
shown to be superior to natural preparations. Ideally,
surfactant would be administered without requiring
mechanical ventilation. An increasing number of studies
investigate the roles of alternative modes of administration
and the use of nasal continuous positive airway pressure to
minimise the need for mechanical ventilation. Whether
children with other lung diseases benefit from surfactant
therapy is less clear. Evidence suggests that infants with
meconium aspiration syndrome and children with acute
lung injury/acute respiratory distress syndrome may benefit,
while no positive effect of surfactant is seen in infants with
congenital diaphragmatic hernia. However, more research is
needed to establish potential beneficial effects of surfactant
administration in children with lung diseases other than
RDS. Furthermore, genetic disorders of surfactant metabo-
lism have recently been linked to respiratory diseases of
formerly unknown origin. It is important to consider these
disorders in the differential diagnosis of unexplained
respiratory distress although no established treatment is
yet available besides lung transplantation for the most
severe cases. Conclusion: Research around surfactant is
evolving and recent developments include further evolution
of synthetic surfactants, evaluation of surfactant as a
therapeutic option in lung diseases other than RDS and
the discovery of genetic disorders of surfactant metabolism.
Ongoing research is essential to continue to improve
therapeutic prospects for children with serious respiratory
disease involving disturbances in surfactant.
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Abbreviations
ABCA3 ATP-binding cassette transporter A3
ALI acute lung injury
ARDS acute respiratory distress syndrome
bLES bovine lipid extract surfactant
BPD bronchopulmonary dysplasia
CHD congenital diaphragmatic hernia
CLD chronic lung disease
ECMO extracorporeal membrane oxygenation
MAS meconium aspiration syndrome
nCPAP nasal continuous positive airway pressure
RCT randomised controlled trial
RDS respiratory distress syndrome
rSP recombinant surfactant protein
RSV respiratory syncytial virus
SP surfactant protein
Introduction
Surfactant is a complex mixture of lipids (90%) and
proteins (10%) lining the epithelial surface of the lung.
Four surfactant apoproteins have been described: the
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hydrophobic surfactant protein B (SP-B) and SP-C and the
hydrophilic SP-A and SP-D. Surfactant is synthesised by
alveolar type II cells, stored in lamellar bodies that are
exocytosed and taken up into the monolayer lining the
alveolar epithelium. Traditionally, surfactant is recognised
for its surface tension-lowering properties, by which
alveolar collapse is prevented and gas exchange is
facilitated. More recently, surfactant has been shown to
have an important additional role in innate defence of the
lung. Key players in this role are SP-A and D, members of
the collectin family of proteins. Among their functions are
binding, opsonisation and clearance of microbes from the
lung and regulation of immune cell activity. Several
reviews have addressed their role in detail [80, 148].
Evidence is now accumulating that SP-B, SP-C and the
surfactant lipids may be involved in modulation of
pulmonary inflammation as well [21, 30, 44, 71, 101, 117].
The relevance of surfactant for pulmonary physiology is
highlighted by the respiratory distress syndrome (RDS)
seen in preterm infants, caused by an absolute deficiency
of surfactant. Affected infants experience respiratory
insufficiency often requiring mechanical ventilation. The
introduction of exogenous surfactant administration for
these infants is generally regarded as one of the most
important advancements in the field of neonatology,
having significantly decreased neonatal mortality over the
last 25 years. Nowadays, the potential benefit of surfactant
therapy is evaluated in a wide range of respiratory
disorders in both neonates and paediatric patients. More-
over, several disease entities of formerly unknown origin
have recently been linked to genetic disorders of surfactant
metabolism.
The purpose of this review is to give an overview of
these and other recent developments in the field of
surfactant, focusing on clinically relevant issues in neona-
tology and paediatrics.
Surfactant in RDS
In 1959 Avery and Mead established the relationship
between surfactant deficiency and RDS seen in preterm
infants [9]. Twenty years later, exogenous surfactant was
successfully administered to preterm infants with RDS and
shown to dramatically improve oxygenation in these babies
[51]. In subsequent clinical trials, reductions in neonatal
mortality and incidence of pneumothorax were found after
surfactant administration [1]. Further trials found that early
treatment is superior to late treatment [151], multiple doses
are better than a single dose [122] and prophylactic
surfactant is associated with better outcome than is rescue
treatment [125]. Excellent reviews on the history of surfactant
are available [57, 107].
In recent years knowledge of the in vivo surfactant
metabolism in RDS patients has increased as a result of
metabolic studies. Preterm infants were shown to have a
decreased surfactant pool size with decreased synthesis but
increased recycling of surfactant when compared to term
infants [152]. Furthermore, it was found that both prenatal
steroids and exogenous surfactant administration after birth
stimulate endogenous surfactant synthesis [25, 26].
Recent developments in surfactant treatment for RDS
include new comparative trials of natural surfactants,
exploration of alternative modes of administration and
evaluation of the use of nasal continuous positive airway
pressure (nCPAP) either to decrease the need for surfactant
or as an adjuvant therapy following surfactant administra-
tion. Moreover, much effort is put into the development of
synthetic surfactants for treatment of respiratory distress.
This topic is discussed separately.
Natural surfactant
In recent years, several clinical trials have compared the
efficacy of different natural surfactants in the treatment of
RDS. Natural surfactants are generally derived from either
lung lavage or minced lung of bovine or porcine origin.
Four studies have compared beractant (Survanta) and
poractant-α (Curosurf) [12, 93, 112, 126]. Curosurf was
found to have a more rapid onset of action in most studies
[93, 112, 126]. A meta-analysis of these studies plus one
unpublished study suggested a significant decrease in
neonatal mortality after Curosurf treatment [57]. However,
three of these studies have compared a Curosurf dose of
200 mg/kg with a Survanta dose of 100 mg/kg [93, 112,
126]. When these studies were excluded from analysis, the
difference in mortality after treatment with comparable
doses of both surfactants was not statistically significant
[57]. Malloy and colleagues reported a significant decrease
in the incidence of persistent ductus arteriosus after
Curosurf treatment [93]. None of the other studies found
such an effect and it is unclear whether this difference may
be explained by the dosing difference as well.
Baroutis and colleagues compared the effects of three
different surfactant preparations: Curosurf, Survanta and
Alveofact [12]. Treatment with either Curosurf or Alveofact
was associated with a decrease in days on the ventilator,
days on oxygen and hospital stay, but no significant
improvement in morbidity and mortality. A more recent
study comparing Survanta and Alveofact reported a
decrease in chronic lung disease (CLD) with Survanta
[59]. However, CLD was defined as oxygen need at 28 days
of age, a definition that does not take into account the
gestational age of the infant and is generally regarded to be
imprecise and outdated. There was a decrease in days on
the ventilator, days on oxygen and length of hospital stay
890 Eur J Pediatr (2007) 166:889–899
with Survanta. The need for postnatal steroids was
decreased in the Survanta group as well; however, their
overall use was very high compared to current standards.
Two studies have compared Survanta and Infasurf
(calfactant) for the treatment of RDS [7, 17]. The largest
study compared the efficacy of the two surfactants for
prophylactic administration as well as for rescue treatment
[17]. Infasurf was found to have a more rapid effect,
without having an effect on overall incidence of broncho-
pulmonary dysplasia (BPD) or mortality. Subgroup analysis
showed a decrease in mortality after prophylactic Survanta
treatment in infants under 600 g. A more recent, smaller
study reported a decrease in number of doses required with
Infasurf without any differences in outcome [7].
One small comparative trial was reported on bovine lipid
extract surfactant (bLES) and Survanta [86]. Treatment with
bLES was associated with a more rapid improvement in
oxygenation, yet no effect on short-term outcome was seen.
In summary, most differences in effectiveness between
natural surfactant preparations are short-lived. On the basis
of currently available evidence, no preparation can clearly
be considered superior to another with regard to morbidity
and mortality. More data would be needed and future
studies should include comparison of long-term outcome
parameters. However, the clinical relevance of these differences
is likely to be minimal; therefore, future studies should focus
on more relevant aspects of surfactant therapy.
Timing of surfactant
Many studies have investigated the ideal timing of surfactant
administration. Systematic reviews of earlier studies have
found a decrease in the incidence of pneumothorax, pulmo-
nary interstitial emphysema, CLD and mortality with early
(within 2 h after birth) versus delayed surfactant administra-
tion [151] and a decrease in pneumothorax and mortality
with prophylactic surfactant administration versus selective
rescue therapy [125].
As stressed by Horbar and colleagues, these trials were
conducted at a time when the use of antenatal steroid
administration was much lower than it is today. Therefore,
the observed difference between early and delayed surfac-
tant therapy may be smaller in current practice [69]. A more
recent trial still suggests a positive effect of early surfactant
administration in intubated infants, albeit without any effect
on morbidity and mortality [88].
Surfactant and nCPAP
An important issue is the use of nCPAP, either to prevent
intubation and surfactant administration or to accelerate
extubation after surfactant is given. A recent Cochrane
review showed that intubation and early administration of
surfactant followed by extubation to nCPAP was associated
with decreased ventilator requirement, but an increase in
number of surfactant administrations when compared to
selective surfactant and continued ventilation [129]. No
difference in BPD incidence was detected. Dani and
colleagues later showed that, when intubated and given
surfactant, infants may benefit from early extubation to
nCPAP [40]. Whether intubation for the purpose of
surfactant administration is favourable for larger preterms
with mild to moderate RDS is questioned by a recent study
showing an increase in median duration of ventilation with
elective intubation and surfactant [46].
The potential of the initial use of nCPAP to prevent
intubation and administration of surfactant is the subject of
current studies. Potential side effects of intubation and high
costs of surfactant administration might thus be avoided.
Retrospective studies suggest that, when compared to early
initiation of mechanical ventilation, early nCPAP decreases
the incidence of intraventricular haemorrhage and improves
survival but may increase the risk for necrotising enteroco-
litis when nCPAP fails [2, 5]. However, only part of the
infants on early mechanical ventilation received surfactant.
More recent data from Te Pas and colleagues suggest that
even if early nCPAP fails, it may still result in a decreased
BPD risk when compared to infants intubated in the delivery
room [133].
Ideally, avoidance of intubation and subsequent mechan-
ical ventilation would involve early initiation of nCPAP in
combination with an alternative mode of surfactant admin-
istration. The combined use of early nCPAP and surfactant
administration through a thin endotracheal catheter was
reported to decrease the need for mechanical ventilation in
very low birth weight infants [83]. Other potential
alternatives for endotracheal administration include aerosoli-
sation [48], bronchoscopic administration [14], nasopharyn-
geal deposition [77] and administration of surfactant via a
laryngeal mask [22, 136]. Clearly, controlled trials are needed
to evaluate the safety of alternative modes of surfactant
administration and the potential of a combined approach with
early nCPAP to decrease the subsequent need for mechanical
ventilation and improve outcome.
Synthetic surfactant
A major disadvantage of commercially available natural
surfactants is their price. Therefore much effort has been
put into development of synthetic surfactants. The basis of
these preparations is a highly simplified phospholipid
mixture. The lack of surfactant proteins is a disadvantage
compared to natural surfactants. Natural surfactant prepa-
rations contain variable amounts of SP-B and SP-C that
enhance surface tension-lowering properties and long
favoured their use above synthetic preparations [123]. The
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potential of several additives with surfactant protein-like
properties to increase the efficacy of synthetic surfactant
preparations is currently under evaluation.
Two synthetic surfactants containing such additives have
been tested in clinical trials. One is Venticute, which
contains recombinant SP-C (rSP-C). However, no trials
involving Venticute in preterms with RDS have yet been
published. The other, lucinactant (Surfaxin), is character-
ised by the addition of KL4 (sinapultide), a non-natural
polypeptide that was designed to resemble SP-B [38]. Two
trials comparing prophylactic use of Surfaxin to a natural
surfactant in the treatment of RDS showed no differences in
relevant outcome parameters [99, 121]. However, these
trials were designed to show only ‘noninferiority’, and the
study comparing three surfactant preparations was under-
powered to detect a difference between Surfaxin and the
natural surfactant Survanta [76].
So although synthetic surfactants, especially those with
surfactant protein-like additives, have theoretical advan-
tages over natural surfactants, to date none has been shown
to be superior to natural preparations in comparative trials
[38]. Yet the search for new synthetic surfactant protein
analogues goes on. Recent data from in vitro and animal
studies are promising regarding efficacy of different SP-B
peptides, modified rSP-C with improved function and
polymyxin B as possible future additives to synthetic
surfactants [38]. Moreover, a group of additives capable
of decreasing surfactant inactivation is under investigation,
showing promising results. These include chitosan [153],
hyaluronan [91, 92, 141], dextran [108] and polymyxin B
[27, 130]. The potential of these additives lies in their use in
RDS and meconium aspiration syndrome (MAS), where
inactivation of surfactant by albumin and meconium
respectively decreases its efficiency.
Surfactant in other neonatal lung disease
Congenital diaphragmatic hernia (CDH)
CDH is a serious disease associated with a mortality of 25–
74%, primarily due to respiratory insufficiency [43].
Surfactant deficiency and dysfunction have been found in
a lamb CDH model and respiratory failure in these animals
improved after exogenous surfactant administration [143].
Data on surfactant pool size and function in infants with
CDH are inconclusive [33, 35, 74, 85]. Only one small,
randomised trial of surfactant in CDH patients on extracor-
poreal membrane oxygenation (ECMO) is available, show-
ing no benefit [89]. Incidental reports do suggest a
beneficial effect [10, 18, 53]. Recently, the CDH study
group has retrospectively compared the outcomes of CDH
infants that did and did not receive exogenous surfactant
during admission. No difference was observed in term infants
[137], while surfactant administration was associated with
increased mortality in preterms [85]. However, this difference
was not statistically significant after adjusting for gestational
age and Apgar score. When only infants on ECMO were
considered, surfactant still did not improve survival [36].
In conclusion, although surfactant therapy is incorporat-
ed in CDH treatment protocols in many centres, this
strategy is not supported by evidence and is advised to be
used only in the context of a randomised trial [43, 100].
Meconium aspiration syndrome (MAS)
Perinatal meconium aspiration affects surfactant function
and metabolism in several ways. Meconium has an
extremely high surface tension [116], inhibits surfactant
function [11, 66, 98, 132] and causes pneumonitis with
direct toxicity to alveolar type II cells [68, 109]. Further-
more, we have recently found decreased alveolar surfactant
content and synthesis in infants with MAS [73].
Possible treatment options for MAS involving surfactant
include bolus surfactant administration and lung lavage
using either saline or diluted surfactant. Initial case series
reported temporary improvements in oxygenation and a
decreased need for ECMO after bolus surfactant treatment
[8, 79]. Two randomised trials of bolus surfactant therapy
have been published [47, 90]. A meta-analysis of these
studies showed a decreased need for ECMO in surfactant-
treated infants without any relevant improvement in
outcome [124]. An important difference between the two
studies was the timing of surfactant administration. With
early treatment (within 6 h after birth), Findlay and colleagues
did report additional beneficial effects, such as decreased
air leaks and shorter duration of ventilation [47]. Based on
current evidence, Dargaville and Mills advocate early ad-
ministration of a surfactant known to resist meconium
inactivation in severely affected infants, with repeated doses
when needed [41].
Meconium can be effectively removed from the lung by
lavage [87]. Most studies report a subsequent improvement
in oxygenation above pre-lavage baseline, with earlier
extubation and a decrease in pneumothorax incidence
[41]. Two randomised controlled trials (RCT) of lavage
therapy in MAS have been reported. Only limited data are
available from one study, suggesting that surfactant lavage
is better than saline lavage [110]. No significant differences
were found between infants lavaged with Surfaxin and non-
lavaged infants in the other trial [147]. However, additional
studies are underway [41]. Further trials should focus on
the comparison between bolus surfactant therapy and
surfactant lavage.
In conclusion, infants with MAS seem to benefit from
surfactant therapy when started early and repeated when
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necessary. There is insufficient evidence as yet to support
the use of surfactant lavage therapy for MAS outside the
setting of a clinical trial [41]. As discussed earlier, the
development of synthetic additives capable of decreasing
meconium-induced surfactant inhibition may help to in-
crease future efficacy of surfactant therapy for MAS.
Other neonatal lung diseases
Decreases in alveolar surfactant pool size and surfactant
recycling have been described in chronically ventilated
infants progressing to or suffering from BPD [32, 34, 127].
Therefore, surfactant might be beneficial in treating these
infants. Indeed, incidental reports suggest short-term im-
provement after surfactant administration in chronically
ventilated preterms, urging the need for further studies [15,
78, 96]. Other neonatal pulmonary disorders that may
benefit from surfactant therapy include haemorrhagic
pulmonary oedema [4] and neonatal pneumonia [64], yet
once again only incidental reports addressing these issues
are available.
Surfactant in paediatrics
Surfactant has been evaluated as a potential intervention in
respiratory diseases beyond the neonatal period. Several
reports have focused on the use of surfactant in acute
respiratory distress syndrome (ARDS) or acute lung injury
(ALI). In paediatric ARDS/ALI patients, acute improve-
ment of oxygenation is seen with surfactant administration
[65, 94, 97, 144–146]. No additional effects on outcome
were noted in the first RCT [97]. In a more recent RCT in
ventilated children with respiratory failure and bilateral
radiographic abnormalities, treatment with Infasurf was
associated with a decrease in mortality [145]. The mortality
effect was greatest in the subgroup of infants (age <1 year),
yet overall mortality was not significantly different after
adjustment for immunocompromised status. Concerns
about the study being underpowered and the increased
incidence of hypotension and transient hypoxaemia in the
treatment group warrant further evaluation before surfactant
administration can be routinely recommended in paediatric
ARDS/ALI [39]. An important determinant of surfactant
response seems to be the nature of the lung injury causing
the respiratory failure. Patients with direct lung injury may
benefit more than do patients with indirect lung injury
[145]. Future studies should address differences in ALI
aetiology in the patients studied.
Several studies have investigated a possible role for
surfactant in treatment of bronchiolitis. A recent systematic
review evaluating three trials reported a significant decrease
in duration of ventilation and of hospital admission with
surfactant therapy [138]. However, it is generally felt that
current evidence is insufficient to establish the role of
surfactant suppletion in bronchiolitis and that additional
trials are needed [42, 81, 138].
Surfactant disturbances have been described in a wider
range of paediatric lung diseases and recent case series
suggest a potential beneficial role for surfactant in the
treatment of lobar atelectasis [82], intrapulmonary haemor-
rhage [55], Pneumocystis carinii pneumonia [37] and as an
adjuvant therapy in ECMO patients [63]. Clearly, additional
studies are needed to establish the safety and potential
benefit of surfactant therapy in these disorders as well.
Genetic disorders of surfactant
SP-B deficiency
In recent years, several genetic disorders affecting surfac-
tant metabolism have been identified. SP-B deficiency, first
described in 1993 [104], is the most serious of these. It is a
rare autosomal recessively inherited disease, in the majority
of patients caused by the 121ins2 mutation [105]. SP-B is
critical for lowering alveolar surface tension. Adding to the
surfactant dysfunction caused by the deficiency of SP-B is
the associated incomplete processing of SP-C [139]. In
almost all cases a total absence of SP-B is present, which is
invariably lethal [60]. Babies present with respiratory
failure shortly after birth, only partially and transiently
being responsive to exogenous surfactant administration.
To date, the only therapeutic option for these patients is
lung transplantation, which should be performed within
weeks to months [61]. Recently, Palomar and colleagues
reported that the outcome for lung transplantation in SP-
B-deficient patients is comparable to patients transplanted
for other reasons [111]. However, Hamvas reports that
approximately half the families of children eligible for
lung transplantation decline and another 30% of patients
die awaiting transplantation [60].
SP-C-associated disease
In recent years, several mutations in the SP-C gene have
been identified and connected to respiratory disease. The
incidence of SP-C-associated disease appears to be consid-
erably higher than that of SP-B deficiency [60]. This is
partly due to the fact that SP-C mutations are inherited in a
dominant manner [60]. On the other hand, approximately
half of the disease-associated mutations are spontaneous
mutations [60]. The most common mutation I73T, as well
as most other mutations, results in production of misfolded
SP-C that accumulates within the alveolar type II cell [13,
75, 140].
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The presentation and characteristics of respiratory diseases
resulting from SP-C mutations are diverse and unpredictable
[60]. Patients carrying mutations may present anywhere
between the newborn period and adulthood. In a large cohort
of term newborns with unexplained respiratory disease, the
incidence of SP-C gene mutations was shown to approach
10% [142]. Asymptomatic patients carrying SP-C mutations
have also been identified [28, 134]. Newborns may present
with RDS-like symptoms despite term birth. In paediatric
patients interstitial lung disease may present with gradual
onset of respiratory insufficiency, hypoxaemia and failure to
thrive. Some patients remain stable or even improve, while
others progress to respiratory insufficiency, eventually
requiring lung transplantation.
No standard treatment for SP-C-associated disease is
available. Some authors have seen clinical improvement
after treatment with hydroxychloroquine [3, 114] or repeat-
ed lung lavage along with administration of corticosteroids
and azathioprine [135], while others have not [19, 31].
Clearly, additional studies are needed to further investigate
possible treatment options for SP-C-associated disease.
ABCA3-associated disease
The most recently discovered genetic disruption of surfac-
tant metabolism is caused by mutations in the gene
encoding for ABCA3 [119]. ABCA3 is an ATP-binding
cassette (ABC) protein localised at the limiting membrane
of lamellar bodies [102, 149]. In vitro studies show that
depending on the mutation present, the mutant ABCA3
protein is either retained at the endoplasmic reticulum or is
appropriately localised yet exhibits a decreased capacity to
hydrolyse ATP [95]. The exact role of ABCA3 is unknown;
however, other members of the ABCA protein family are
involved in lipid transport [128]. A specific role for
ABCA3 in lipid metabolism is further supported by the
detection of reduced lung levels of phosphatidylglycerol
and phosphatidylcholine subtypes in ABCA3 knockout
mice, while levels of other phospholipids and cholesterol
were unaffected [49]. Along with other studies, this work
further suggests a key role for ABCA3 in lamellar body
formation [29, 49, 103]. Abnormal lamellar body forma-
tion, surfactant deficiency and surfactant dysfunction have
indeed been found in patients carrying ABCA3 mutations
[20, 23, 52, 119].
Most patients with ABCA3 mutations described thus far
presented in the neonatal period with progressive respira-
tory distress, often being lethal. Hydroxychloroquine and
corticosteroids have been used in the management of
ABCA3-associated disease, yet their efficiency in treating
the disorder is unclear [23]. For these patients, lung
transplantation is currently the only treatment option [24,
52]. However, Bullard and colleagues have recently stressed
the fact that most patients described thus far were derived
from highly selected populations of infants with unexplained
severe respiratory distress [23]. The same group has
identified ABCA3 mutations in paediatric patients with
interstitial lung disease, suggesting that defects in ABCA3
may be involved in a greater range of respiratory diseases
[24]. Research on ABCA3-associated respiratory disease is
clearly evolving and knowledge about the disorder will
increase in the near future.
Wewish to underline the importance of considering genetic
disorders of surfactant metabolism in the differential diagnosis
of both unexplained respiratory failure and interstitial lung
disease in the newborn period and beyond. When such a
disorder is suspected in a patient, one should turn to a
specialised laboratory for establishment of the diagnosis.
Surfactant protein polymorphisms and lung disease
In addition to the mutations described above, more
common polymorphisms in surfactant proteins have been
linked to both increased and decreased risks of developing
neonatal and paediatric pulmonary disease. Genetic variants
of the SP-B gene have been linked to increased risks for
both respiratory distress [50, 62] and BPD [115]. Common
SP-A alleles, in interaction with the SP-B Ile131Thr
genotype, have been associated with RDS susceptibility,
while others seem to decrease RDS risk [56, 58]. Recently,
polymorphisms in SP-C genes have also been linked to
RDS [84]. The susceptibility for respiratory syncytial virus
(RSV) infection is altered by polymorphisms of SP-A and
SP-D, known modulators of innate immunity. In addition,
associations of surfactant protein polymorphisms with
extrapulmonary diseases exist, such as recurrent ear
infections [113] and meningococcal disease [72].
The relevance of these associations between surfactant
protein haplotypes and neonatal and paediatric pulmonary and
infectious diseases remains unclear. Associations may differ
between populations, hence the finding of contrasting risk
associations between SP-B polymorphisms and RDS [62].
Larger studies are clearly needed to confirm current findings.
Possible future applications include individual risk determi-
nation and subsequent surfactant protein administration.
Future directions and conclusion
As highlighted in this review, substantial progression has
been made in recent years considering the role of surfactant
therapy in neonatal and paediatric lung diseases. However,
many questions remain unanswered. Efforts should be
made to investigate the roles of nCPAP and alternative
administration routes for surfactant in the treatment of
preterm infants. Further development of synthetic surfac-
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tants to enhance their surface tension-lowering properties
and capacity to withstand inactivation may increase future
efficacy of surfactant therapy. More ideally, one should be
able to stimulate endogenous surfactant synthesis in
preterm infants, preferably antenatally. A potential candi-
date drug would be docosahexaenoic acid, which has been
shown to stimulate synthesis of dipalmitoyl phosphatidyl-
choline, the major phospholipid in surfactant, in preterm
mice when administered to the mother during pregnancy
[16]. Another promising future application for surfactant is
its use as a carrier for drug administration directly into the
lung. In this way drugs are allowed to act locally with
minimisation of unwanted systemic effects. Possible candi-
date drugs include immunosuppressants [54], vasodilators
[106] and β-sympathicomimetics [150]. Investigational
drugs that have been administered in animal models using
surfactant as a carrier include a 5-lipoxygenase inhibitor [6]
and recombinant human Clara cell secretory protein
(rhCC10) [118]. Both agents have been shown to decrease
experimental lung injury in these models. The anti-
inflammatory and antimicrobial characteristics of SP-A
and SP-D make them attractive potential therapeutic agents
as well. Administration of recombinant SP-D fragments in
animal models results in enhanced pulmonary clearance of
RSV [67], a reduced allergic response [45, 120, 131] and
prevention of endotoxin shock [70]. However, SP-A and
SP-D are very large and complex molecules, making
construction of functional recombinant whole proteins
extremely difficult if not impossible. Much more research
is needed to evaluate a possible role for surfactant proteins
in the treatment of inflammatory diseases. Furthermore, the
general evolution of gene therapy involves potential
applications in the genetic disorders of surfactant metabo-
lism, primarily SP-B deficiency.
More than 25 years after the introduction of exogenous
surfactant therapy, research around surfactant is still evolv-
ing. Surfactant remains a hallmark in the treatment of RDS,
especially in very preterm infants. Future research should
focus on potential ways to avoid intubation and mechanical
ventilation and give surfactant via an alternative route. The
therapeutic role of surfactant in other neonatal and paediatric
lung diseases is less clear and needs further evaluation.
Finally, genetic disorders of surfactant metabolism should be
taken into account in the differential diagnosis of respiratory
distress and interstitial lung disease in children.
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